Closed call


The BBVA Foundation-Hospital Clínic Barcelona Advanced Research Contracts are aimed at specialists in the Health Sciences, with experience in research, who wish to further their scientific specialization by undertaking a specific project related to the strategic research lines of Campus Clínic, pursued jointly by Hospital Clínic Barcelona and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS):

  • Biological aggression and response mechanism
  • Liver, digestive system and metabolism
  • Oncology and hematology
  • Respiratory, cardiovascular and renal pathobiology and bioengineering

Clinical neuroscience These contracts, awarded annually since 2021 to candidates with a profile of demonstrable excellence, bear the names of doctors Joan Rodés and Josep Baselga, in recognition of two exceptionally innovative and transformative figures in biomedicine, whose many contributions remain present today in numerous facets of the best clinical practice and advanced translational research.

Project selected in Clinical Neuroscience:

“Advanced MRI and AI-Driven prognostics in smoldering Multiple Sclerosis: Developing a comprehensive methodology for evaluating and predicting disease progression” 

Multiple sclerosis is characterized by pathogenic mechanisms leading to neuroaxonal damage from the onset of the disease, also called latent MS. The main aim of this project is to identify a risk signal by integrating imaging metrics, including magnetic resonance imaging and optical coherence tomography with biological metrics to determine precisely a series of significant markers using artificial intelligence and to formulate a prognostic tool capable of predicting clinical outcomes with regard to disability risk.

Researcher: Alberto Calvi, postdoctoral researcher at the Hospital Clínic Barcelona Research Foundation-August Pi i Sunyer Biomedical Research Institute (FRCB-IDIBAPS).

The contract is worth €300,000 (€100,000 per year for three years)

Project selected in Oncology and Haematology:

“Deciphering the effect of endocrine therapy and CDK4/6 inhibitors in early Estrogen Receptor Positive Breast Cancer on the molecular phenotypes for biomarker discovery and immunotherapeutic opportunities”

CDK4/6 inhibitors have transformed the treatment of breast cancer, in particular as a first-line treatment for estrogen receptor-positive/HER2-negative and metastatic breast cancer and as adjuvant therapy for selected patients with high-risk early breast cancer.  The aim of the project is to identify the mechanisms of resistance to standard treatment, thus generating hypotheses for personalized treatment, including de-escalation approaches and additional immunotherapeutic agents.

Researcher: Milana Arantza Bergamino Sirvén, clinical research fellow at the Catalan Institute of Oncology (ICO).

The contract is worth €300,000 (€100,000 per year for three years)